The latest foray into use of AI in drug discovery has been agreed between Sanofi and Exscientia, under which the privately-owned Scottish group will use its technology platform to seek out and validate combinations of drug targets for use by the French group to develop novel medicines.
Exscientia's platform will applied to its bispecific-small-molecule design strategy, by which a small molecule is designed to be
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?